# EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

Study · id `cardio:ct-nct02816736` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02816736](<https://clinicaltrials.gov/study/NCT02816736>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02816736

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 365 participants.

## Technical summary

Registry record NCT02816736. Randomized; triple masking; primary purpose treatment. Start 2017-03-02 (actual); primary completion 2020-09-15 (actual). Results posted on 2021-12-03.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 365 participants (enrolled count; ClinicalTrials.gov record NCT02816736, source copy `cardio:ctgov-nct02816736-2021-12-03`, retrieved 2026-10-26)
- Started: 2017-03-02 (actual) (ClinicalTrials.gov record NCT02816736, source copy `cardio:ctgov-nct02816736-2021-12-03`, retrieved 2026-10-26)
- Primary completion: 2020-09-15 (actual) (ClinicalTrials.gov record NCT02816736, source copy `cardio:ctgov-nct02816736-2021-12-03`, retrieved 2026-10-26)
- Completion: 2020-09-29 (actual) (ClinicalTrials.gov record NCT02816736, source copy `cardio:ctgov-nct02816736-2021-12-03`, retrieved 2026-10-26)
- Results first posted: 2021-12-03 (ClinicalTrials.gov record NCT02816736, source copy `cardio:ctgov-nct02816736-2021-12-03`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02816736, source copy `cardio:ctgov-nct02816736-2021-12-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02816736-2021-12-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)
- Acronym: HFN-LIFE
- Condition: Heart Failure
- Intervention (Drug): LCZ696
- Intervention (Drug): valsartan
- Intervention (Drug): LCZ696 placebo
- Intervention (Drug): valsartan placebo
- Lead sponsor: Duke University
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Sacubitril/valsartan (combination) (`cardio:sacubitril-valsartan`)
- Registry intervention name matches this record: Valsartan (`cardio:valsartan`)
- Registry lists this organization as the lead sponsor: Duke University (`cardio:org-duke-university`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial (`cardio:pubmed-34730769`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 53118fd7d80c6d507091c4e67aa858c77524a758b3d0c7ed5fae742861b8187a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
